Growth Hormone Treatment for Idiopathic Short Stature

Assessment Criteria for Short Stature

Short stature requiring intervention is typically defined as height below the 3rd percentile (or height standard deviation score below -1.88) with height velocity below the 25th percentile for age and sex 1, 2
Before considering GH therapy, other potentially treatable risk factors for growth failure must be adequately addressed 3
A thorough evaluation should rule out familial short stature, constitutional delay of growth, hypothyroidism, and occult disease as causes for short stature 4

Treatment should be stopped when height velocity drops below 2 cm per year and/or epiphyseal growth plate closure is evident on radiography 5

At 13 years of age, a female patient is likely in puberty, which significantly affects growth potential and response to GH therapy 6
Pubertal stage assessment (Tanner staging) is essential as growth potential diminishes with advancing puberty 7
Bone age assessment is crucial to determine remaining growth potential before considering GH therapy 8

Regular monitoring of growth velocity and pubertal progression is recommended to ensure no underlying pathology develops 6
Addressing any nutritional deficiencies or other modifiable factors affecting growth should be prioritized 7